These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33828015)

  • 21. Relapsing pure red cell aplasia associated with B-cell chronic lymphocytic leukemia successfully treated by intravenous immunoglobulin concentrate.
    Castelli R; Vismara A; Pavia G; Dagani R; Porro T
    Ann Ital Med Int; 2002; 17(1):47-50. PubMed ID: 11975114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Disseminated cryptococcosis during ibrutinib treatment for chronic lymphocytic leukemia].
    Kumekawa H; Watanabe D; Tamura K; Mizuchi D
    Rinsho Ketsueki; 2022; 63(1):62-65. PubMed ID: 35135954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polyneuropathies associated with IgM monoclonal gammopathies.
    Kelly JJ; Adelman LS; Berkman E; Bhan I
    Arch Neurol; 1988 Dec; 45(12):1355-9. PubMed ID: 2461693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
    Solman IG; Blum LK; Burger JA; Kipps TJ; Dean JP; James DF; Mongan A
    Leuk Res; 2021 Mar; 102():106520. PubMed ID: 33611131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broad alterations of self-reactive antibody-repertoires of plasma IgM and IgG in B-cell chronic lymphocytic leukemia (B-CLL) and B-CLL related target-restricted autoimmunity.
    Stahl D; Lacroix-Desmazes S; Sibrowski W; Kazatchkine MD; Kaveri SV
    Leuk Lymphoma; 2001 Jun; 42(1-2):163-76. PubMed ID: 11699204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
    Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
    J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibrutinib-Induced Skin Rash.
    Kirar S; Gogia A; Gupta R; Mallick S
    Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
    [No Abstract]   [Full Text] [Related]  

  • 28. Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ozbagcivan O; Akarsu S; Nazli EC; Lebe B; Fetil E
    Ann Hematol; 2021 Jan; 100(1):293-294. PubMed ID: 32221651
    [No Abstract]   [Full Text] [Related]  

  • 29. [Peripheral neuropathy occurring soon after cord blood transplantation].
    Harada S; Hayashi H; Tadera N; Iwama K; Kajiwara K; Kouzai Y; Koudo H
    Rinsho Ketsueki; 2016 Apr; 57(4):472-6. PubMed ID: 27169453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Management of Ibrutinib-Induced Thrombocytopenia in a Patient with Chronic Lymphocytic Leukemia: No Interruption, Only Reduction.
    Erdem S; Nalçacı M
    Turk J Haematol; 2024 Mar; 41(1):55-56. PubMed ID: 38131309
    [No Abstract]   [Full Text] [Related]  

  • 31. Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
    Martín-Moro F; García-Cosío M; Marquet-Palomanes J; López-Gutiérrez M; Pian-Arias H; López-Jiménez FJ
    Ann Hematol; 2022 Jan; 101(1):213-215. PubMed ID: 33423076
    [No Abstract]   [Full Text] [Related]  

  • 32. Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report.
    Le TH; Kumar V; Gondal K; Barnes M; Siddique H; Buttar B; Kaell A
    BMC Infect Dis; 2020 Feb; 20(1):175. PubMed ID: 32093604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Sun C; Tian X; Lee YS; Gunti S; Lipsky A; Herman SE; Salem D; Stetler-Stevenson M; Yuan C; Kardava L; Moir S; Maric I; Valdez J; Soto S; Marti GE; Farooqui MZ; Notkins AL; Wiestner A; Aue G
    Blood; 2015 Nov; 126(19):2213-9. PubMed ID: 26337493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies.
    Latov N
    Ann Neurol; 1995 May; 37 Suppl 1():S32-42. PubMed ID: 8968215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
    Lunn MP; Nobile-Orazio E
    Cochrane Database Syst Rev; 2006 Apr; (2):CD002827. PubMed ID: 16625561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients.
    Cassin R; Visentin A; Giannarelli D; Noto A; Mauro FR; Baldini L; Trentin L; Reda G
    Hematol Oncol; 2021 Feb; 39(1):141-144. PubMed ID: 33034902
    [No Abstract]   [Full Text] [Related]  

  • 37. Chronic neutrophilic leukemia associated with chronic lymphocytic leukemia.
    Ito K; Usuki K; Iki S; Urabe A
    Int J Hematol; 1998 Jul; 68(1):87-94. PubMed ID: 9713172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.
    Patel KK; Isufi I; Kothari S; Davidoff AJ; Gross CP; Huntington SF
    Blood; 2020 Oct; 136(17):1946-1955. PubMed ID: 32518952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
    Molica S; Gianfelici V; Levato L
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
    [No Abstract]   [Full Text] [Related]  

  • 40. [Successful treatment with rituximab in two cases of IgM-monoclonal gammopathy of undetermined significance (MGUS) neuropathy].
    Koike M; Sugimoto K; Tusui M; Yahata Y
    Rinsho Ketsueki; 2012 Apr; 53(4):450-4. PubMed ID: 22687979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.